The Goldman Sachs Group Issues Pessimistic Forecast for Dynavax Technologies (NASDAQ:DVAX) Stock Price

Dynavax Technologies (NASDAQ:DVAX) had its price target dropped by equities researchers at The Goldman Sachs Group from $12.00 to $10.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “sell” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s price target suggests a potential downside of 2.88% from the stock’s current price.

Other analysts also recently issued research reports about the company. StockNews.com raised Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Monday, February 24th. HC Wainwright restated a “buy” rating and issued a $31.00 target price on shares of Dynavax Technologies in a report on Friday, February 21st. Finally, William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 21st.

Dynavax Technologies Stock Performance

NASDAQ:DVAX opened at $10.30 on Thursday. The stock has a market capitalization of $1.28 billion, a P/E ratio of 57.21 and a beta of 1.26. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. Dynavax Technologies has a 12-month low of $9.74 and a 12-month high of $14.63. The stock has a 50-day moving average price of $12.98 and a 200 day moving average price of $12.56.

Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, meeting the consensus estimate of $0.05. The company had revenue of $72.03 million during the quarter, compared to analysts’ expectations of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. Equities research analysts forecast that Dynavax Technologies will post 0.32 EPS for the current fiscal year.

Institutional Trading of Dynavax Technologies

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DVAX. SG Americas Securities LLC purchased a new stake in shares of Dynavax Technologies in the fourth quarter worth approximately $990,000. Nordea Investment Management AB increased its stake in Dynavax Technologies by 42.7% in the 4th quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company’s stock worth $10,034,000 after buying an additional 232,690 shares during the period. Palumbo Wealth Management LLC purchased a new position in Dynavax Technologies in the 4th quarter worth about $275,000. Barclays PLC lifted its holdings in Dynavax Technologies by 137.4% during the 3rd quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company’s stock valued at $3,371,000 after buying an additional 175,118 shares in the last quarter. Finally, Fox Run Management L.L.C. purchased a new stake in Dynavax Technologies in the 4th quarter valued at about $883,000. 96.96% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.